Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

41 results about "Lauromacrogol" patented technology

Lauromacrogol 400 is a medicine available in a number of countries worldwide. A list of US medications equivalent to Lauromacrogol 400 is available on the Drugs.com website.

Application of lauromacrogol injection as medicament for treating internal hemorrhoid

InactiveCN102198089AEliminate or reduce dilationEliminate or reduce congestionOrganic active ingredientsPharmaceutical delivery mechanismDiseaseFibrosis
The invention belongs to the field of the medical application of a lauromacrogol injection, and particularly relates to application of a lauromacrogol injection as a medicament for treating internal hemorrhoid. Internal hemorrhoid is one of hemorrhoids, which occurs above the pectinate line of the anal canal and is a commonly encountered disease having the highest incidence rate among the hemorrhoids; for majorities of people, internal hemorrhoid bleeding is a disease difficult to deal with; and when the internal hemorrhoid bleeds too much, secondary anemia can be caused. In the invention, the lauromacrogol injection is injected into the hemorrhoid, so that an aseptic inflammation is produced and is then gradually fiberized, thus realizing the treatment of the internal hemorrhoid. The lauromacrogol injection can wrap veins and arterioles in the hemorrhoid, so that a protective layer can be formed at the peripheries of the veins and arterioles, thereby preventing weak blood vessels from bleeding due to damage caused by defecation and other factors; fiber textures can occlude blood vessel cavities, eliminate or lessen the expansion and congestion of the veins and atrophy the hemorrhoid; because of the fiberization process, a relaxed mucous membrane can be fixed on the muscular wall thereunder again through the fiber textures, thereby eliminating the symptom.
Owner:SHAANXI TIANYU PHARMA

Stable multilayer-film structural foaming agent and preparation method thereof

The invention particularly relates to a stable multilayer-film structural foaming agent and a preparation method of the stable multilayer-film structural foaming agent. The technical scheme is that the preparation method comprises steps as follows: getting 20 to 50wt% of main agent, 20 to 50wt% of assistant and 20 to 50wt% of foam stabilizer as the raw materials at 15 to 25 DEG C; then adding foam stabilizer of which the mass is 10 to 20 times that of the raw materials mentioned above; and agitating for 5 to 15 minutes, so as to obtain the stable multilayer-film structural foaming agent, wherein the main agent is one of sodium lauryl sulfate, sodium dodecyl benzene sulfonate, sodium dodecyl sulfate, alkylphenol ethoxylates and fatty alcohol-polyoxyethylene ether; the assistant is one of dodecanol, polyethylene glycol, setanol, octadecanol and lauromacrogol; and the foam stabilizer is one of sodium carboxymethylcellulose, gelatin, sodium carboxymethyl starch, arabia gum adhesive and hydroxyethyl cellulose. The preparation method has the characteristics of being simple, convenient to operate, and short in preparation time and the like; and the prepared stable multilayer-film structural foaming agent is relatively small in dimension, uniform in distribution, full in foaming and high in stability.
Owner:WUHAN UNIV OF SCI & TECH

Application of lauromacrogol injection as drug for curing cesarean scar pregnancy

The invention relates to the field of lauromacrogol injection drug application, and discloses application of lauromacrogol injection as a drug for curing cesarean scar pregnancy. The drug is applied according to the following steps: step (1), a focus scope, a muscular layer thickness and the blood supply situation of a focus location are determined by ultrasound contrast; step (2), the vagina is conventionally disinfected and a towel is spread at a lithotomy position of a patient; step (3), under ultrasonic guidance, the lauromacrogol injection is injected at a peripheral muscular layer of a gestational sac and around the gestational sac, until annular or flaky reinforcement of the gestational sac is seen under ultrasound and peripheral blood is sparse, wherein the specification of the lauromacrogol injection is that each 10ml of injection contains 100mg of lauromacrogol. According to the application of the lauromacrogol injection as the drug for curing cesarean scar pregnancy, the lauromacrogol injection is adhered to the inside of a vessel at the injection site, thus prompting a fibrosis strip to replace the pathological vessel, resulting in permanent occlusion of the vessel around the gestational sac, interdicting an open vessel at the pathological location, and greatly reducing bleeding risk in induced abortion operation.
Owner:张淑珍

Refining process of laurinol and process for preparing lauromacrogol by using refined product as raw material

The invention relates to a refining process of laurinol and a process for preparing lauromacrogol by using a prepared laurinol refined product as a raw material. According to the preparation process of the lauromacrogol, impurities in the lauromacrogol are effectively reduced, a dehydration step in a lauromacrogol synthesis process is reduced, and energy consumption is reduced, so that the preparation process is suitable for industrial production; all indexes of the prepared lauromacrogol meet the requirements of EP and Chinese pharmacopoeia, the lauromacrogol has good oxidation resistance and high temperature resistance, can be stably stored at room temperature in the presence of air, and solves the problem that an existing lauromacrogol product needs to be stored at low temperature under the protection of inert gas, and the stability of the lauromacrogol is improved; and the lauromacrogol can be stored without special packaging, so that the production, storage and transportation costs are greatly reduced, effective support is provided for the production of the lauromacrogol preparation, the medication expenditure of patients is greatly reduced, and the lauromacrogol is beneficial to the majority of patients.
Owner:BEIJING ENCHENG KANGTAI BIOLOGICAL TECH

Modified lauromacrogol foam hardening agent as well as preparation method and application thereof

The invention discloses a modified lauromacrogol foam hardening agent as well as a preparation method and application thereof. The preparation method comprises the following steps: firstly, mixing a lauromacrogol bulk drug with gelatin or agar powder with surface activity and foam stabilizing effect through an ultra-stable homogeneous formula technology to prepare a modified lauromacrogol mother solution, and obviously improving the foam stability and defoaming time of the foam hardening agent prepared from the modified lauromacrogol mother solution; subjecting the modified lauromacrogol mother liquor and various active ingredients including a preparation with a photosensitive (thermal) characteristic, a nuclear magnetic resonance imaging preparation, a chemotherapeutic drug, nuclide and the like to ultrasonic mixing to obtain a multifunctional improved lauromacrogol mixed preparation, and then preparing the multifunctional and visual lauromacrogol foam hardening agent under the action of a three-way valve device. The modified lauromacrogol foam hardener for varicose veins and tumors is locally administered in a minimally invasive mode, and then a good treatment effect on the varicose veins and the tumors is achieved in combination with a sclerotherapy and other therapies.
Owner:XIAMEN UNIV

Medicine for interventional treatment of uterine myoma

The invention provides a medicine for interventional treatment of uterine myoma. The medicine belongs to a polyoxyethylene lauryl alcohol ether compound, called lauromacrogol for short; after lauromacrogol is injected under the envelope of an uterine myoma body, a layer of fibre textures is formed in the lower layer of the envelope; blood vessels are injured and permanently occluded by the fibre textures, so that the uterine myoma body is reduced and gradually disappears; uterine myoma is subjected to interventional treatment by utilizing the medicine, so that the functions of an uterus can be intactly retained; in addition, fertilization is not influenced; operative wound and a series of post-operative complications are avoided; the effect of the medicine disclosed by the invention is comparable with operation in the aspect of symptom improvement; by means of interventional treatment of uterine myoma by utilizing the medicine, the medicine disclosed by the invention is small in wound, rapid in recovery, free from being in hospital and easy for patients to accept; compared with the traditional operative treatment, interventional treatment of uterine myoma by utilizing the medicine is simple and convenient; furthermore, blood transfusion is generally unnecessary; the medicine disclosed by the invention has the advantages of being minimally invasive, repeatable, accurate for locating, high in curative effect, rapid in effect, few in complications and the like and brings a good development prospect for clinical treatment of uterine myoma.
Owner:AFFILIATED HOSPITAL OF NANTONG UNIV

Application of hyaluronic acid combined with lauromacrogol in preparation of foam sclerosing medicine for treating venous malformation

The invention discloses application of lauromacrogol combined hyaluronic acid in preparation of a medicine for treating venous malformed foam sclerosis. The lauromacrogol combined hyaluronic acid is prepared to form a foam hardening agent in particular application. The preparation method of lauromacrogol combined hyaluronic acid comprises the following steps: pumping lauromacrogol, hyaluronic acid and injection water by using an injector, and uniformly shaking and mixing; pumping sterile air by the other injector, wherein the two injectors are connected by a medical tee-joint valve; and feeding a plurality of times in a Tessari method, and mixing to form uniform and stable foam. According to the application, the foam hardening agent is prepared from the lauromacrogol combined hyaluronic acid and used for treating venous malformation, so that the half time of foam can be remarkably prolonged, and the curative effect can be improved. Currently, the method is successfully adopted in the stomatological department of Qilu Hospital of Shandong University, 20 cases with large-area venous malformation in maxillofacial region are treated, and the clinical effect is remarkable.
Owner:SHANDONG UNIV QILU HOSPITAL

Transdermal absorption preparation

A transdermal absorption promotion composition comprising the following components (a), (b), and (c) and a transdermal absorption preparation comprising the following components (a), (b), (c), and (d) are disclosed. (a) propylene glycol (b) a polyol fatty acid ester (c) lauromacrogol (d) a drug component The transdermal absorption promotion composition and transdermal absorption preparation not only exhibit an excellent transdermal absorption promotion effect, but also exhibit superior skin-permeability, even if a drug having a relatively high lipophilic property and poor transdermal absorbability is used, exhibit a favorable feeling of use, and are safe and stable.
Owner:HISAMITSU PHARM CO INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products